Plain-English translation of NCT07800871 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called for people with five types of autoimmune diseases: vasculitis, inflammatory muscle disease, rheumatoid arthritis, lupus, and systemic sclerosis. is made from donated immune cells that are designed to reduce the harmful B cells that drive autoimmune disease. The study will test whether this treatment is safe and whether it helps people whose disease hasn't gotten better with at least two other medications.
Many people with autoimmune diseases don't respond well to standard treatments, leaving them with ongoing pain, organ damage, and disability. This trial is exploring whether this new medication—which works differently than existing drugs—might help patients who have run out of options.
You likely qualify if…
You likely don't qualify if…
You will receive as an infusion, either alone or combined with other medications and possibly a brief conditioning regimen to prepare your body. The study has two stages: first, researchers will carefully increase doses to find the safest level, then enroll more people at that dose level. You'll have frequent visits early on to check for side effects, with follow-up visits continuing for up to 2 years, and then long-term safety check-ins for up to 15 years after your first treatment.
AI-generated summary from trial data · Sep 17, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Fate Therapeutics
Enrollment target
~446 participants
Started
October 2026
Primary completion
October 2028
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Fate Clinical Trials
Fate Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.